Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to buy. On October 21, Exelixis, Inc. (NASDAQ:EXEL) ...

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients.

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Exelixis (NASDAQ: EXEL) is set to give its latest quarterly earnings report on Tuesday, 2025-11-04. Here's what investors need to know before the announcement. Analysts estimate that Exelixis will ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

I am upgrading Exelixis to a 'Buy' due to de-risked pipeline and strong financials. Positive phase 3 STELLAR-303 results for zanzalintinib in refractory mCRC mark a major breakthrough and growth ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best ...

Mitsubishi UFJ Trust & Banking Corp trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 3.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 92,009 ...

Exelixis, Inc. (NASDAQ:EXEL) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 24, Stephens upgraded the company’s stock to “Overweight” from “Equal Weight” with a price ...